The Chairman & CEO of MiMedx Group (NASDAQ: MDXG) is Buying Shares

By George MacDonald

Today, the Chairman & CEO of MiMedx Group (NASDAQ: MDXG), Parker Petit, bought shares of MDXG for $139.8k.

In addition to Parker Petit, 8 other MDXG executives reported Buy trades in the last month. Over the last month, Parker Petit has reported 3 Buy trades on MDXG for a total of $811.6k.

Based on MiMedx Group`s latest earnings report from March 31, the company posted quarterly revenue of $53.37M and quarterly net profit of $1.2M. In comparison, last year the company earned revenue of $40.77M and had a net profit of $4.09M. The company has a one year high of $13.20 and a one year low of $6.64. MDXG’s market cap is $767.4M and the company has a P/E ratio of 29.21%.

Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $12.33, reflecting a -43.1% downside. Six different firms, including Brean Capital and Canaccord Genuity, currently also have a Buy rating on the stock.

Looking at blogger coverage of MDXG, there is a 100% Bullish tendency on the stock, in relation to a 75% average bullish tendency within the Healthcare sector.

Over the last 3 months, the insider sentiment on MiMedx Group has been positive based on 24 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

MiMedx Group, Inc. developes, manufactures and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.